Event Details

Featured Videos

Nanobiotix KOL Call to Discuss the Role of NBTXR3 and Immune Oncology in Advancing Head & Neck Cancer

Nanobiotix will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST.

The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the 2024 Annual Meeting of American Society for Clinical Oncology (ASCO), showing disease control and tumor response in patients treated with radiotherapy-activated NBTXR3 followed by anti-PD-1 for 2nd line or further in patients with recurrent or metastatic head and neck squamous cell carcinoma naïve or resistant to prior anti-PD-1 therapy.

Topics will include:
•      NBTXR3’s mechanisms of action
•      NBTXR3’s local and systemic response
•      How head and neck cancer patients present and are treated in this setting; unmet needs
•      NBTXR3 in recurrent/metastatic head and neck cancer, the 1100 study

1/4) How NBTXR3 Works and its Local and Systemic Responses – Sebastien Paris, PhD
2/4) Challenges and Opportunities in Recurrent/Metastatic Head and Neck Cancer - Ari Rosenberg, MD
3/4) NBTXR3 in R/M HNSCC, the 1100 Study – Colette Shen, MD PhD
4/4) Panel session: the Role of NBTXR3 and Immune Oncology in Advancing Head&Neck Cancer | 05.18.24